Development asset linked to Takeda in public FDA and regional records.
pharma · Diabetes Mellitus · Hemophilia A
Takeda
Takeda drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 1993
- Employees
- 1,617
- Programs
- 1179
- Drugs
- 359
- Patents
- 1436
Takeda pipeline
Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Takeda drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Takeda in public FDA and regional records. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial urease.
- Target
- Bacterial urease
- Mechanism
- Bacterial urease inhibitor
-
US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.
- Target
- Sodium/potassium-transporting ATPase
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
-
adalimumab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Placenta growth factor inhibitor
-
agalsidase alfa
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Takeda's portfolio. Molecular target: Globotriosylceramide.
- Target
- Globotriosylceramide
- Mechanism
- Globotriosylceramide hydrolytic enzyme
-
agalsidase beta
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Globotriosylceramide.
- Target
- Globotriosylceramide
- Mechanism
- Globotriosylceramide hydrolytic enzyme
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved.
-
allogeneic t cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (δlngfr) and the herpes simplex i virus thymidine kinase (hsv-tk mut2)
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Takeda's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
alogliptin
Alimentary tract and metabolism (A10)US regulatory status: approved. Mechanism: Dipeptidyl peptidase IV inhibitor.
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
US regulatory status: approved.
-
alogliptin benzoate
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.
- Target
- Dipeptidyl peptidase 4
- Mechanism
- Dipeptidyl peptidase IV inhibitor
-
alpha1-proteinase inhibitor (human)
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Takeda's portfolio. Molecular target: Neutrophil elastase.
- Target
- Neutrophil elastase
- Mechanism
- Leukocyte elastase inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
amifampridine
Nervous system (N07)US regulatory status: approved. Molecular target: Voltage-gated potassium channel.
- Target
- Voltage-gated potassium channel
- Mechanism
- Voltage-gated potassium channel blocker
-
US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in Takeda's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Mechanism: Removal of necrotic tissue.
- Mechanism
- Removal of necrotic tissue
-
anagrelide
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Takeda's portfolio. Mechanism: Phosphodiesterase 3 inhibitor.
- Mechanism
- Phosphodiesterase 3 inhibitor
-
US regulatory status: approved. Molecular target: Phosphodiesterase 3.
- Target
- Phosphodiesterase 3
- Mechanism
- Phosphodiesterase 3 inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Takeda's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to Takeda in public FDA and regional records.
-
apremilast
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
Development asset linked to Takeda in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
-
Development asset linked to Takeda in public FDA and regional records.
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
azilsartan medoxomil
Cardiovascular system (C09)US regulatory status: approved. Mechanism: Type-1 angiotensin II receptor antagonist.
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
binimetinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
blinatumomab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- T cell surface glycoprotein CD3 cross-linking agent
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
brentuximab vedotin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
brigatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- ALK tyrosine kinase receptor inhibitor
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Takeda in public FDA and regional records. Mechanism: Dopamine transporter inhibitor.
- Mechanism
- Dopamine transporter inhibitor
-
c1 inhibitor (human)
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in Takeda's portfolio. Molecular target: Coagulation factor XI.
- Target
- Coagulation factor XI
- Mechanism
- Coagulation factor XI inhibitor
-
cabozantinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Mechanism: Hepatocyte growth factor receptor inhibitor.
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
caffeine
Nervous system (N06)US regulatory status: approved. Molecular target: Adenosine receptor.
- Target
- Adenosine receptor
- Mechanism
- Adenosine receptor antagonist
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Takeda in public FDA and regional records. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins
Musculo-skeletal system (M09)Musculo-skeletal system (M09) compound in Takeda's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter substrate
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
clopidogrel
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Takeda's portfolio. Mechanism: Purinergic receptor P2Y12 antagonist.
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
US regulatory status: approved. Molecular target: P2Y purinoceptor 12.
- Target
- P2Y purinoceptor 12
- Mechanism
- Purinergic receptor P2Y12 antagonist
-
Development asset linked to Takeda in public FDA and regional records.
-
colchicine
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Takeda's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 2A.
- Target
- 5-hydroxytryptamine receptor 2A
- Mechanism
- Serotonin 2c (5-HT2c) receptor antagonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase A.
- Target
- Peptidyl-prolyl cis-trans isomerase A
- Mechanism
- Cyclophilin A modulator
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
damoctocog alfa pegol
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Takeda's portfolio. Molecular target: Coagulation factor VIII.
- Target
- Coagulation factor VIII
- Mechanism
- Coagulation factor VIII exogenous protein
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
darbepoetin alfa
Blood and blood forming organs (B03)US regulatory status: approved. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
darvadstrocel
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Takeda's portfolio. Mechanism: Unknown.
- Mechanism
- Unknown
-
dasatinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
- Target
- Bcr/Abl fusion protein
- Mechanism
- SRC inhibitor
-
dengue tetravalent vaccine (live, attenuated)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Takeda's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
deucravacitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Non-receptor tyrosine-protein kinase TYK2.
- Target
- Non-receptor tyrosine-protein kinase TYK2
- Mechanism
- Tyrosine-protein kinase TYK2 negative allosteric modulator
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Takeda in public FDA and regional records. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter releasing agent
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Norepinephrine transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium/potassium-transporting ATPase.
- Target
- Sodium/potassium-transporting ATPase
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Takeda's portfolio.
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Takeda's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
doxorubicin hydrochloride
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Plasma kallikrein.
- Target
- Plasma kallikrein
- Mechanism
- Plasma kallikrein inhibitor
-
emicizumab
Blood and blood forming organs (B02)US regulatory status: approved. Molecular target: Coagulation factor IX and X.
- Target
- Coagulation factor IX and X
- Mechanism
- Coagulation factor IX and X other
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
epoetin delta
Blood and blood forming organs (B03)Blood and blood forming organs (B03) compound in Takeda's portfolio. Molecular target: Erythropoietin receptor.
- Target
- Erythropoietin receptor
- Mechanism
- Erythropoietin receptor agonist
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records. Mechanism: Serotonin transporter inhibitor.
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Sodium-dependent serotonin transporter.
- Target
- Sodium-dependent serotonin transporter
- Mechanism
- Serotonin transporter inhibitor
-
US regulatory status: approved. Molecular target: Glutamate [NMDA] receptor.
- Target
- Glutamate [NMDA] receptor
- Mechanism
- Glutamate [NMDA] receptor negative allosteric modulator
-
esomeprazole
Alimentary tract and metabolism (A02)Alimentary tract and metabolism (A02) compound in Takeda's portfolio. Mechanism: Potassium-transporting ATPase inhibitor.
- Mechanism
- Potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
everolimus
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
ex vivo expanded autologous human corneal epithelial cells containing stem cells
Sensory organs (S01)Sensory organs (S01) compound in Takeda's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
exagamglogene autotemcel
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in Takeda's portfolio. Molecular target: BCL11 transcription factor A.
- Target
- BCL11 transcription factor A
- Mechanism
- B-cell lymphoma/leukemia 11A gene editing negative modulator
-
Development asset linked to Takeda in public FDA and regional records.
-
febuxostat
Musculo-skeletal system (M04)US regulatory status: approved. Molecular target: Xanthine dehydrogenase/oxidase.
- Target
- Xanthine dehydrogenase/oxidase
- Mechanism
- Xanthine dehydrogenase inhibitor
-
fenofibrate
Cardiovascular system (C10)US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
US regulatory status: approved. Molecular target: Mu-type opioid receptor.
- Target
- Mu-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
-
US regulatory status: approved. Mechanism: Supplement.
- Mechanism
- Supplement
-
ferumoxytol
Blood and blood forming organs (B03)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
follitropin beta
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in Takeda's portfolio. Molecular target: Follicle-stimulating hormone receptor.
- Target
- Follicle-stimulating hormone receptor
- Mechanism
- Follicle stimulating hormone receptor agonist
-
Development asset linked to Takeda in public FDA and regional records.
-
fruquintinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor alpha.
- Target
- Peroxisome proliferator-activated receptor alpha
- Mechanism
- Peroxisome proliferator-activated receptor alpha agonist
-
US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
glucagon
Systemic hormonal preparations (H04)US regulatory status: approved. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon receptor agonist
-
US regulatory status: approved. Molecular target: Sulfonylurea receptor 1, Kir6.2.
- Target
- Sulfonylurea receptor 1, Kir6.2
- Mechanism
- Sulfonylurea receptor 1, Kir6.2 blocker
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
guanfacine
Cardiovascular system (C02)Cardiovascular system (C02) compound in Takeda's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to Takeda in public FDA and regional records.
-
human fibrinogen
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in Takeda's portfolio. Molecular target: Fibrinogen.
- Target
- Fibrinogen
- Mechanism
- Fibrinogen exogenous protein
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Takeda's portfolio.
-
human normal immunoglobulin
Antiinfectives for systemic use (J06)Antiinfectives for systemic use (J06) compound in Takeda's portfolio. Mechanism: Replacement therapy, immunomodulatory effects.
- Mechanism
- Replacement therapy, immunomodulatory effects
-
human protein c
Blood and blood forming organs (B01)Blood and blood forming organs (B01) compound in Takeda's portfolio. Molecular target: Vitamin K-dependent protein C.
- Target
- Vitamin K-dependent protein C
- Mechanism
- Vitamin K-dependent protein C exogenous protein
-
US regulatory status: approved. Molecular target: Hyaluronic acid.
- Target
- Hyaluronic acid
- Mechanism
- Hyaluronic acid hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
hydrocortisone
Systemic hormonal preparations (H02)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to Takeda in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to Takeda in public FDA and regional records.
-
icatibant
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in Takeda's portfolio. Mechanism: Bradykinin B2 receptor antagonist.
- Mechanism
- Bradykinin B2 receptor antagonist
-
US regulatory status: approved. Molecular target: B2 bradykinin receptor.
- Target
- B2 bradykinin receptor
- Mechanism
- Bradykinin B2 receptor antagonist
-
idursulfase
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Heparan sulfate.
- Target
- Heparan sulfate
- Mechanism
- Heparan sulfate hydrolytic enzyme
-
imatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Takeda's portfolio. Mechanism: Tyrosine-protein kinase ABL inhibitor.
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
infliximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Takeda's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Takeda's portfolio.
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Takeda in public FDA and regional records.
-
interferon beta-1a
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
Development asset linked to Takeda in public FDA and regional records.
-
ixazomib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Takeda's portfolio. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteasome inhibitor
-
US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
lanadelumab
Blood and blood forming organs (B06)Blood and blood forming organs (B06) compound in Takeda's portfolio. Molecular target: Plasma kallikrein.
- Target
- Plasma kallikrein
- Mechanism
- Plasma kallikrein inhibitor
-
US regulatory status: approved. Molecular target: Plasma kallikrein.
- Target
- Plasma kallikrein
- Mechanism
- Plasma kallikrein inhibitor